Genomic diversity of colorectal cancer: Changing landscape and emerging targets

Table 3 Current ongoing immune therapy trials for colorectal cancer

Agent	Class of agent	Phase	Trial number1	Comment
MK-3475	Anti-PD-1 mAb	II	NCT01876511	MSI-high tumors
MEDI4736	Anti-PD-L1 mAb	I/II	NCT01693562
Nivolumab ± ipiliumumab	Anti-PD-1 mAb/anti-CTLA-4 mAb	I/II	NCT02060188	Recurrent and metastatic CRC
MK-3475 + mFOLFOX6	Anti-PD-1 mAb	II	NCT02375672
Tremelimumab + MEDI4736	Anti-CTLA-4 mAb + anti-PD-L1 mAb	I	NCT01975831

¹Utilizing the NCT number, clinical trial information can be obtained at https://clinicaltrials.gov. mAb: Monoclonal antibody; CRC: Colorectal cancer; MSI: Microsatellite instability; CTLA: Cytotoxic T associated lymphocyte protein; PD-1: Program cell death protein 1; PD-L1: Programmed cell death protein ligand 1; FOLFOX: Combination of 5-Flurouracil, folinic acid and oxaliplatin chemotherapy regimen.